Table 3 Relation of demographics, lipid profile, and disease-related data with cholesterol efflux capability in SSc patients and controls
From: HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
Cholesterol efflux capacity beta coef. (CI95%), p | ||
|---|---|---|
Controls (n = 115) | Patients (n = 73) | |
Age, years | − 0.03 (− 0.35 to 0.30), 0.88 | − 0.04 (− 0.11 to 0.04), 0.32 |
Male | − 3.34 (− 11.34 to 4.66), 0.41 | − 1.67 (− 4.81 to 1.47), 0.29 |
Body mass index, kg/m2 | − 0.18 (− 0.59 to 0.24), 0.41 | 0.14 (0.00 to 0.28), 0.050 |
Abdominal circumference, cm | − 0.13 (− 0.27 to 0.02), 0.097 | 0.09 (0.03 to 0.14), 0.002 |
Systolic blood pressure, mmHg | − 0.14 (− 0.27 to 0.00), 0.057 | 0.01 (− 0.03 to 0.06), 0.57 |
Diastolic blood pressure, mmHg | − 0.02 (− 0.06 to 0.02), 0.39 | 0.01 (− 0.05 to 0.08), 0.67 |
Cardiovascular comorbidities | ||
Smoking | 4.05 (− 1.39 to 9.50), 0.14 | 1.50 (− 0.47 to 3.47), 0.13 |
Diabetes | 0.81 (− 7.72 to 9.35), 0.85 | 1.63 (− 0.87 to 4.12), 0.20 |
Hypertension | − 2.75 (− 7.00 to 1.51), 0.20 | 0.41 (− 1.25 to 2.07), 0.62 |
Statins | − 2.73 (− 9.16 to 3.69), 0.40 | 0.35 (− 1.32 to 2.02), 0.68 |
Analytical and lipid profiles | ||
CRP, mg/dl | ||
Cholesterol, mg/dl | 0.04 (− 0.02 to 0.09), 0.17 | 0.01 (− 0.01 to 0.03), 0.35 |
Triglycerides, mg/dl | − 0.02 (− 0.06 to 0.03), 0.43 | 0.01 (− 0.01 to 0.02), 0.36 |
HDL cholesterol, mg/dl | 0.08 (− 0.03 to 0.20), 0.16 | − 0.00 (− 0.07 to 0.07), 0.97 |
LDL cholesterol, mg/dl | 0.02 (− 0.04 to 0.08), 0.43 | 0.01 (− 0.01 to 0.03), 0.19 |
LDL:HDL cholesterol ratio | − 0.31 (− 2.78 to 2.17), 0.81 | 0.11 (− 0.42 to 0.64), 0.69 |
Non-HDL cholesterol, mg/dl | 0.01 (− 0.04 to 0.07), 0.66 | 0.01 (− 0.01 to 0.03), 0.37 |
Lipoprotein A, mg/dl | 0.04 (− 0.02 to 0.11), 0.16 | 0.01 (− 0.01 to 0.02), 0.41 |
Apolipoprotein A1, mg/dl | 0.03 (− 0.03 to 0.09), 0.33 | 0.01 (− 0.02 to 0.03), 0.62 |
Apolipoprotein B, mg/dl | − 0.01 (− 0.10 to 0.09), 0.91 | 0.01 (− 0.02 to 0.04), 0.58 |
Apo B:Apo A ratio | − 5.19 (− 18.11 to 7.73), 0.43 | − 0.39 (− 3.34 to 2.56), 0.79 |
Atherogenic index | − 0.52 (− 2.63 to 1.60), 0.63 | 0.01 (− 0.50 to 0.52), 0.97 |
SS- and treatment-related data | ||
log Disease duration, years | − 0.51 (− 1.47 to 0.45), 0.29 | |
Modified Rodnan skin score, units | − 0.19 (− 0.34 to − 0.04), 0.014 | |
Raynaud phenomenon | − 0.54 (− 2.89 to 1.80), 0.64 | |
Digital ulcers | − 2.50 (− 4.99 to 0.01), 0.049 | |
Calcinosis | − 0.53 (− 3.25 to 2.18), 0.70 | |
Arthritis | 0.28 (− 2.26 to 1.71), 0.78 | |
Gastric reflux | 0.87 (− 0.78 to 2.53), 0.30 | |
Pathological esophageal manometry | 0.15 (− 1.78 to 2.08), 0.88 | |
Interstitial lung disease | − 1.34 (− 3.24 to 0.55), 0.16 | |
Pulmonary hypertension | − 1.14 (− 3.15 to 0.86), 0.26 | |
Anti-centromere antibody positivity | − 0.34 (− 2.08 to 1.40), 0.70 | |
Anti-Scl70 antibody positivity | 1.80 (− 0.49 to 4.09), 0.12 | |
Current prednisone | − 0.69 (− 2.67 to 1.28), 0.49 | |
log Prednisone | − 2.22 (− 6.83 to 2.40), 0.32 | |
DMARDs | − 0-00 (− 2.33 to 2.33), 0.99 | |
Azathioprine | − 0.33 (− 3.95 to 3.07), 0.80 | |
Methotrexate, n (%) | 0.96 (−3.93 to 5.86), 0.70 | |
Hydroxychloroquine, n (%) | − 0.85 (− 5.74 to 4.05), 0.73 | |